ReviewHuman genetics2015
Progress towards the integration of pharmacogenomics in practice.
Review in Human genetics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 44 citations in OpenAlex.
- High-throughput sequencing: a breakthrough in molecular diagnosis for precision medicine.Functional & integrative genomics · 2025Review
- Pharmacogenomics: Driving Personalized Medicine.Pharmacological reviews · 2023Review
- A review on longitudinal data analysis with random forest.Briefings in bioinformatics · 2023Review
- Precision Medicine in Antidepressants Treatment.Handbook of experimental pharmacology · 2023Review
- Clinical implementation of drug metabolizing gene-based therapeutic interventions worldwide.Human genetics · 2022Review
- Review
- Search and visualization of gene-drug-disease interactions for pharmacogenomics and precision medicine research using GeneDive.Journal of biomedical informatics · 2021Article
- Whole genome sequencing in oncology: using scenario drafting to explore future developments.BMC cancer · 2021Review
- Pharmacogenomics cascade testing (PhaCT): a novel approach for preemptive pharmacogenomics testing to optimize medication therapy.The pharmacogenomics journal · 2021Review
- A Web-Based Pharmacogenomics Search Tool for Precision Medicine in Perioperative Care.Journal of personalized medicine · 2020Article
- Identification of a key candidate gene‑phenotype network mediated by glycyrrhizic acid using pharmacogenomic analysis.Molecular medicine reports · 2019Article
- Bridging the Gaps in Personalized Medicine Value Assessment: A Review of the Need for Outcome Metrics across Stakeholders and Scientific Disciplines.Public health genomics · 2019Review
- Clinical application and importance of one-step human CYP2C19 genotype detection.The Journal of international medical research · 2018Article
- GT-WGS: an efficient and economic tool for large-scale WGS analyses based on the AWS cloud service.BMC genomics · 2018Article
- Genetic variation among 82 pharmacogenes: The PGRNseq data from the eMERGE network.Clinical pharmacology and therapeutics · 2016Article
- Pharmacogenomics in Pediatric Patients: Towards Personalized Medicine.Paediatric drugs · 2016Review
- Whole genome sequencing in pharmacogenomics.Frontiers in pharmacology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Understanding the role genes and genetic variants play in clinical treatment response continues to be an active area of research with the goal of common clinical use. This goal has developed into today's industry of pharmacogenomics, where new drug-gene relationships are discovered and further characterized, published and then curated into national and international resources for use by researchers and clinicians. These efforts have given us insight into what a pharmacogenomic variant is, and how it differs from human disease variants and common polymorphisms. While publications continue to reveal pharmacogenomic relationships between genes and specific classes of drugs, many challenges remain toward the goal of widespread use clinically. First, the clinical guidelines for pharmacogenomic testing are still in their infancy. Second, sequencing technologies are changing rapidly making it somewhat unclear what genetic data will be available to the clinician at the time of care. Finally, what and when to return data to a patient is an area under constant debate. New innovations such as PheWAS approaches and whole genome sequencing studies are enabling a tsunami of new findings. In this review, pharmacogenomic variants, pharmacogenomic resources, interpretation clinical guidelines and challenges, such as WGS approaches, and the impact of pharmacogenomics on drug development and regulatory approval are reviewed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.